Jerome Bernard Zeldis
Independent DirectorDr. Jerome Bernard Zeldis, MD, PhD, also known as Jerry, is Director at NexGelRx, Inc. He is Scientific Advisory Board Member of Serpin Pharma, LLC. Dr. Zeldis is Member of Advisory Board of Frezent Biological Solutions Inc. He served as Executive VP, Head of Research & Development at NexImmune, Inc. since January 2021 until March 31, 2023 and transition to providing consulting and advisory services to the Company for a period ending on March 31, 2024. He is Member of Scientific Advisory Board at Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) since December 2024. He was an Executive Chairman at ViralClear Pharmaceuticals, Inc. from April 2020 to October 2021. He served as Independent Director at Biond Biologics Ltd. since June 2020 until 2023. He served as Member of Scientific Advisory Board at Enveric Biosciences, Inc. since February 2018. He has been an Independent Director of NEXGEL, Inc since April 1, 2020 and serves as its Chairman of Scientific Advisory Board. Dr. Zeldis has been a Director at PTC Therapeutics, Inc. since September 28, 2012. Dr. Zeldis served as Director of BioSig Technologies, Inc. since May 17, 2019 until October 2021. He serves as Member of Scientific Advisory Board at WaveGuide Corporation. Dr. Zeldis had been the Chief Medical Officer and President of Clinical Development at Sorrento Therapeutics, Inc. since August 15, 2016 and had been its President of Clinical Research, Medical Affairs & Regulatory/Head of Clinical Research, Regulatory, Drug Safety, Medical Affairs since September 14, 2017. His employment with Sorrento commenced in August 2016. Dr. Zeldis has also served as Chief Medical Officer of Celularity, Inc. since 2017. Dr. Zeldis served as the Chief Medical Officer, Senior Vice President of Clinical Research & Medical Affairs and Vice President of Medical Affairs of Celgene Corporation. He served as the Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. In that capacity, Dr. Zeldis oversaw clinical trials using Celgene?s molecules He has been employed at Celgene Corporation since February 1997 to June 2016. He has extensive drug development experience gained through his career at Celgene, Inc. Dr. Zeldis joined at Celgene during which he was instrumental in growing Celgene into one of the leading global biopharmaceutical companies. He served as Assistant Professor of Medicine at the Harvard Medical School from July 1987 to September 1988, Associate Professor of Medicine at University of California, Davis from September 1988 to September 1994, Clinical Associate Professor of Medicine at Cornell Medical School from January 1995 to December 2003 and Professor of Clinical Medicine at the Robert Wood Johnson Medical School from July 1998 to June 2010. Dr. Zeldis served as an Associate Director of clinical research and the Director of Medical Development at Sandoz Research Institute and Janssen Pharmaceutical Research Institute. From September 1994 to February 1997, he worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He is an experienced global industry leader with a distinguished career at one of the world's leading biopharmaceutical companies with operations in more than 50 countries and products sold in more than 70 markets in the Americas, Europe and Asia Pacific regions. He served as the Chairman of Alliqua BioMedical, Inc. since November 27, 2012 until December 05, 2017. He was the Chairman of MetaStat, Inc. since May 5, 2017. He served as Vice Chairman of MetaStat, Inc. from April 25, 2016 to May 5, 2017. He serves as Chairman of the board of Semorex Inc., (also known as Semorex Corporation) and Trek Therapeutics. He has been a Director of MetaStat, Inc. since April 25, 2016. Dr. Zeldis was a Director of Celgene Cellular Therapeutics, Inc. (also known as Anthrogenesis Corporation). He has been a Director at IR Biosciences Holdings Inc., since November 1, 2007. He has been an Independent Director of Soligenix, Inc. since June 22, 2011. He serves as a Director of ImmuneRegen BioSciences, Inc. and Trek Therapeutics. He serves on the board of the NJ Chapter of the Arthritis Foundation and the Castleman's Disease Organization. Dr. Zeldis has been a Member of Scientific Advisory Board at Etubics Corporation since July 2015. He served as Member of Scientific Advisory Board at Ovid Therapeutics Inc. since October 2015. He served as a Member of Scientific Advisory Board at Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) and served as its Director since September 2015 until April 25, 2017. He has been a Director of Kalytera Therapeutics, Inc from December 2015 to May 25, 2017. He served as an Independent Director of BioSig Technologies, Inc. since April 9, 2015 until November 9, 2017. He served as Director of Alliqua BioMedical, Inc. from May 17, 2012 to December 5, 2017. He served as a Director at Bionor Pharma ASA from April 11, 2012 to April 28, 2016. He was employed by Celegene from 1997 to 2016. He is a named inventor on 43 US patents. He has published 122 peer reviewed articles and 24 reviews, book chapters and editorials. He trained in internal medicine at the UCLA Center for the Health Sciences and was a research fellow in clinical and gastroenterology at Massachusetts General Hospital and Harvard Medical School. Since April 2020, Dr. Zeldis has been an executive chairman at ViralClear Pharmaceuticals, Inc. Dr. Zeldis holds a BA and an M.Sc. in Molecular Biology from Brown University and M. Phil, MD and PhD in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. He is on the board of Immodulon.
Positions
- Company NameSoligenix, Inc.Stock CodeSNGXPositionIndependent DirectorColleagues
- CJChristopher J. SchaberChairman of the Board of Directors, CEO & President
- JLJonathan L. GuarinoSenior VP, CFO & Corporate Secretary
- ODOreola DoniniSenior VP & Chief Scientific Officer
- ATAdam T. RumageSenior VP of Project Management & Regulatory Affairs
- GAGregory Anthony LapointeIndependent Director
- RJRobert J. RubinIndependent Director
- BPBrian PoligoneChair of Cutaneous T-Cell Lymphoma Medical Advisory Board
- Company NameNEXGEL, Inc.Stock CodeNXGLPositionIndependent Director & Chairman of Scientific Advisory BoardRelated SecuritiesColleagues
- BJBrian J. KieserInterim CEO & Director
- SMSteven Mark GlassmanIndependent Chairman
- IBIan BlackmanChief Financial Officer
- GJGregory J. RobbVice President of Operations
- VPValter PintoManaging Director of KCSA Strategic Communications
- JBJerome Bernard ZeldisIndependent Director & Chairman of Scientific Advisory Board
- SAStephen A. BrigidoMember of Scientific Advisory Board
- SPStephen P. BancoMember of Scientific Advisory Board
